Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 18/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 18/20 | 0.65 |
| ▸ | FLT3 | P36888 | 3/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19885733 | 0.86 | KDM4E (0.58) | PDGFRBPDGFRA | |
| SCHEMBL6870484 | 0.79 | PDGFRB (1.00) | PDGFRBPDGFRAFLT3FGFR1PRKCE | |
| SCHEMBL18114411 | 0.79 | KDM4E (0.62) | PDGFRBPDGFRAFGFR1 | |
| SCHEMBL7000829 | 0.78 | PDGFRB (1.00) | PDGFRBPDGFRAFLT3 | |
| SCHEMBL6870759 | 0.77 | PDGFRB (1.00) | PDGFRBPDGFRAFLT3FGFR1 | |
| SCHEMBL22168428 | 0.76 | SLC6A2 (0.71) | — | |
| SCHEMBL6864994 | 0.75 | PDGFRB (1.00) | PDGFRBPDGFRAFLT3FGFR1PRKCE | |
| SCHEMBL6865103 | 0.75 | FLT3 (1.00) | PDGFRBPDGFRAFLT3FGFR1 | |
| SCHEMBL6435699 | 0.74 | KDM4E (0.56) | PDGFRBPDGFRAFGFR1 | |
| SCHEMBL6868045 | 0.74 | PDGFRB (1.00) | PDGFRBPDGFRAFLT3FGFR1PRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | disclosed |
| EP-1109785-B1 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ZENTARIS AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-6407102-B1 | TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS | ZENTARIS AG (DE) | 2002-06-18 | — | — | US | disclosed |
| EP-1109785-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA Medica Aktiengesellschaft (DE) | 2001-06-27 | — | — | EP | disclosed |
| WO-1999057117-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | PDGFRB 474/4885PDGFRA 542/4885FLT3 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.